BioCentury | Dec 13, 2019
Product Development

Leveraging real-world data to assess the promise of CAR Ts, Dutch style

With the next set of expensive CAR T therapies poised to enter the market based on limited datasets, the Netherlands is proactively gathering the evidence it needs to make reimbursement decisions. The Dutch Health Institute...
BC Extra | Mar 27, 2019
Financial News

With $126M IPO, Precision aims to bring allogeneic CAR T to clinic this half

Precision raised $126.4 million Wednesday in a NASDAQ IPO that values the gene editing company at about $784.5 million. Precision BioSciences Inc. (NASDAQ:DTIL) sold 7.9 million shares at $16, the midpoint of its proposed range....
BC Week In Review | Mar 8, 2019
Financial News

Genome editing company Precision proposes $100M IPO

With plans to bring an allogeneic CAR T immunotherapy into the clinic, Precision BioSciences Inc. (Durham, N.C.) proposed March 1 to raise up to $100 million in an IPO on NASDAQ. Precision plans to start...
BC Extra | Mar 2, 2019
Financial News

Genome editing company Precision proposes $100M IPO

With plans to bring an allogeneic CAR T immunotherapy into the clinic, Precision BioSciences Inc. (Durham, N.C.) proposed Friday to raise up to $100 million in an IPO on NASDAQ. Precision plans to start this...
BC Week In Review | Jun 29, 2018
Company News

AbbVie, Calibr to develop universal CAR T therapies

AbbVie Inc. (NYSE:ABBV) and the California Institute for Biomedical Research (La Jolla, Calif.) partnered to develop universal CAR T therapies using the non-profit's switchable CAR T technology to treat hematological and solid tumors. AbbVie will...
BioCentury | Mar 9, 2018
Finance

CAR T confidence

The first CAR T therapy approvals in the U.S. followed by CFDA guidelines on cell therapy development and manufacturing gave a boost to Chinese investor interest in the space, enabling JW Therapeutics (Shanghai) Co. Ltd....
BioCentury | Jan 27, 2018
Strategy

Jump-starting growth

Celgene Corp.’s two deals this month -- including its largest ever acquisition, of Juno Therapeutics Inc. -- will help fill in the holes left by late-stage failures and commercial disappointments of candidates that were intended...
BC Extra | Aug 9, 2017
Company News

Kite's CAR T to skip advisory committee

On a conference call to discuss its 2Q17 earnings, Kite Pharma Inc. (NASDAQ:KITE) said FDA has informed the company that it will not schedule an advisory committee meeting to discuss a BLA for axicabtagene ciloleucel...
BC Extra | Jul 31, 2017
Company News

Kite submits MAA for CAR T therapy

Kite Pharma Inc. (NASDAQ:KITE) submitted an MAA to EMA for chimeric antigen receptor (CAR) T cell therapy axicabtagene ciloleucel (KTE-C19) to treat relapsed or refractory diffuse large B cell lymphoma (DLBCL), transformed follicular lymphoma and...
BC Extra | Jun 8, 2017
Clinical News

Novartis reports response data for CAR T in DLBCL

Novartis AG (NYSE:NVS; SIX:NOVN) said chimeric antigen receptor (CAR) T cell therapy tisagenlecleucel-T (CTL019) led to a best overall response rate (ORR) of 59% in the pivotal Phase II JULIET trial to treat relapsed or...
Items per page:
1 - 10 of 14